Modulation of the gut-liver axis by oxymatrine alleviates metabolic dysfunction-associated steatotic liver disease

Figure 1 Oxymatrine improves liver function, lipid content, and inflammatory parameters in serum and liver in metabolic dysfunction-associated steatotic liver disease rats. A: Study schematic; B: Body weight trajectory post-oxymatrine, n = 6; C: Representative rat images (final day); D: Gross liver morphology; E: The contents of serum alanine aminotransferase, aspartate transaminase, total cholesterol, triglyceride, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol, n = 6; F: Levels of cytokines including tumor necrosis factor-α, interleukin (IL)-1β, IL-6, and IL-18, n = 6; G: Hepatic triglyceride and free fatty acid contents, n = 6. ^aP < 0.05, ^bP < 0.01. Statistical analysis was conducted using one-way analysis of variance with Tukey’s post hoc test, and results are presented as mean ± SD. ALT: Alanine aminotransferase; AST: Aspartate transaminase; FFA: Free fatty acid; HDL-C: High-density lipoprotein cholesterol; IL: Interleukin; LDL-C: Low-density lipoprotein cholesterol; MET: Metformin; OMT: Oxymatrine; TC: Total cholesterol; TG: Triglyceride; TNF-α: Tumor necrosis factor-α.